Foundation Medicine (NASDAQ:FMI) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, February 20th. Analysts expect Foundation Medicine to post earnings of ($0.99) per share for the quarter.
Foundation Medicine (NASDAQ:FMI) opened at $74.90 on Friday. Foundation Medicine has a 1-year low of $22.40 and a 1-year high of $75.20. The firm has a market capitalization of $2,950.00, a price-to-earnings ratio of -16.76 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03.
Several equities analysts recently commented on FMI shares. Goldman Sachs Group started coverage on Foundation Medicine in a research note on Monday, January 29th. They issued a “neutral” rating and a $73.00 target price for the company. BidaskClub upgraded Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Thursday, January 25th. Zacks Investment Research lowered Foundation Medicine from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Finally, Cowen started coverage on Foundation Medicine in a research note on Thursday. They issued an “outperform” rating and a $90.00 target price for the company. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Foundation Medicine has a consensus rating of “Hold” and a consensus target price of $59.80.
TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2018/02/18/foundation-medicine-fmi-scheduled-to-post-quarterly-earnings-on-tuesday.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.